Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;99(14):e19526.
doi: 10.1097/MD.0000000000019526.

Clinical efficacy and safety of Danhong injection for the treatment of chronic heart failure: A protocol for systematic review

Lihua Han  1 , Chuan Wang  1   2   3 , Dongfeng Yao  1 , Bin Wang  1   2   3 , Zhen Zhang  4 , Jiping Liu  1   2   3
Affiliations

Clinical efficacy and safety of Danhong injection for the treatment of chronic heart failure: A protocol for systematic review

Lihua Han et al. Medicine (Baltimore). 2020 Apr.

Abstract

Background: Danhong injection (DHI) has been widely in the treatment of chronic heart failure (CHF) in China; however, there is not enough clinical evidence DHI for treating CHF.

Methods: Two researchers will search literatures of DHI for CHF in databases. Extracted data are analyzed with Review Manager 5.3 software. The selected studies should be conducted quality evaluation, forest plots and funnel plots will be run by RevMan5.3.

Results: This systematic review validates the clinical efficacy and safety of DHI in the treatment of CHF through the analysis of New York Heart Association functional classification, left ventricular ejection fraction, left ventricular end-diastolic dimension, cardiac output, brain natriuretic peptide, adverse events.

Conclusions: This systematic review will be provided a rational clinical evidence to evaluate the effectiveness and safety of DHI for the treatment of CHF.

Registration number: PROSPERO CRD42019144686.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
PRISMA flowchart of selection studies.
See this image and copyright information in PMC

References

    1. Ewen S, Nikolovska A, Zivanovic I, et al. Chronic heart failure—new insights. Deutsche Medizinische Wochenschrift 2016;141:1560–4. - PubMed
    1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011;8:30–41. - PMC - PubMed
    1. Adorisio R, De Luca L, Rossi J, et al. Pharmacological treatment of chronic heart failure. Heart Fail Rev 2006;11:109–23. - PubMed
    1. Li SN, Li P, Liu WH, et al. Danhong injection enhances angiogenesis after myocardial infarction by activating MiR-126/ERK/VEGF pathway. Biomed Pharmacother 2019;120:109538. - PubMed
    1. Zhao T, Chang L, Zhang B, et al. Specific combination of salvianolic acids as core active ingredients of Danhong injection for treatment of arterial thrombosis and its derived dry gangrene. Front Pharmacol 2017;8:361. - PMC - PubMed

MeSH terms